In a phase 1 trial (NCT01727778), the monoclonal immunoglobulin M antibody PAT-SM6 targeting the cell surface GRP78/BiP (HSPA5) in subjects with relapsed or refractory multiple myeloma demonstrated good tolerability. This evidence concerns the gene HSPA5 and plasma cell myeloma.